There are now some 20 anti-HIV agents available, along with combination therapies, with many more in the development pipeline. In addition to developing more drugs in the established classes, current and future research will focus on new antiviral targets, and great efforts are also being focused on the development of a preventive HIV vaccine. However, in spite of all of the research advances of the past quarter of a century, the challenges are still daunting. Future HIV Therapy keeps researchers and clinicians up-to-date with the significant advances that we hope will ultimately defeat this disease.
Coverage includes:
- Molecular basis of HIV infection
- Virus–host interactions
- Optimal therapeutic approaches, including drug choice and treatment strategies
- Potential future viral targets
- Summaries evaluating newly approved anti-HIV agents
- Postmarketing research, including adverse events and drug safety, pharmacoeconomics and cost–benefit issues in HIV therapy
- Epidemiological studies and trends
- HIV drug resistance
- New and improved diagnostic methods
- Vaccine development, prevention measures and prophylaxis
Articles are subject to peer-review by three independent referees on a double-blind basis. Authors publishing in the journal are asked to disclose any professional or financial interest that may be perceived as causing a conflict of interest in the context of the article.
Future HIV Therapy participates in the HINARI program. The HINARI program, set up by WHO together with major publishers, enables developing countries to gain access to one of the world's largest collections of biomedical and health literature.
